指南与共识心力衰竭与心肌病

心力衰竭治疗的证据图景、监管决策与指南转化

Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines.
指南 / 共识 · J Am Coll Cardiol · 2025-01-01

该综述梳理了2015年以来美国FDA批准的心衰治疗药物及其证据基础与指南转化情况。HFrEF领域批准6种药物,仅2种降低死亡率;HFpEF领域批准3种药物,均未降低死亡率。另有4项HFpEF试验达到主要终点,相关药物正在审评中。

要点

  • 2015年后FDA批准的HFrEF药物中仅沙库巴曲缬沙坦和达格列净降低死亡率。
  • HFpEF领域已批准3种药物但均未显示降低死亡率。
  • 非奈利酮、司美格鲁肽、替尔泊肽的HFpEF试验达主要终点,正在审评。

核心结论

  • 2015年以来FDA批准的心衰药物中,HFrEF领域仅2种降低死亡率,HFpEF领域无药物降低死亡率。

研究设计与样本

  • 本文为state-of-the-art综述,分析2015年以来FDA批准的心衰治疗药物的证据支持及指南纳入情况。

主要发现

  • FDA批准6种药物用于HFrEF以降低发病率或死亡率并改善功能容量,其中仅沙库巴曲缬沙坦(PARADIGM-HF)和达格列净(DAPA-HF)降低死亡率。
  • FDA批准3种药物用于HFpEF以降低发病率或死亡率,但均未降低死亡率。
  • 4项HFpEF试验达到主要终点:非奈利酮(FINEARTS-HF)、2项司美格鲁肽(STEP-HFpEF/DM)、替尔泊肽(SUMMIT),相关药物正在审评。
  • 2015年前FDA批准11种药物用于慢性稳定性HFrEF但无用于HFpEF者,除地高辛仅降低心衰住院外,其余均降低死亡率与发病率。

关键数值与推荐

  • HFrEF获批药物中仅沙库巴曲缬沙坦(PARADIGM-HF试验)和达格列净(DAPA-HF试验)降低死亡率。
  • HFpEF获批的3种药物均未降低死亡率。

临床怎么用

  • 心内科医生应知晓HFrEF药物中仅沙库巴曲缬沙坦和达格列净有死亡率获益证据。
  • HFpEF现有获批药物无死亡率获益,非奈利酮、司美格鲁肽、替尔泊肽等正在审评中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the last decade, the U.S. Food and Drug Administration has approved 6 drugs to reduce morbidity or mortality and improve functional capacity in patients with heart failure with reduced ejection fraction (HFrEF) and 3 drugs to reduce morbidity or mortality in patients with heart failure with preserved ejection fraction (HFpEF). Of the drugs approved for HFrEF, only 2 reduced mortality (sacubitril/valsartan in the PARADIGM-HF trial and dapagliflozin in the DAPA-HF trial). None of the drugs approved for HFpEF reduced mortality. Four trials, 1 with finerenone (FINEARTS-HF trial), 2 with semaglutide (STEP-HFpEF/DM trial), and 1 with tirzepatide (SUMMIT trial) met their primary endpoint in patients with HFpEF and are currently under review for approval. In contrast, before 2015, the U.S. Food and Drug Administration approved 11 drugs (captopril, enalapril, valsartan, candesartan, long-acting metoprolol succinate, bisoprolol, carvedilol, digoxin, isosorbide dinitrate-hydralazine, spironolactone, and epleronone) for patients with chronic stable HFrEF but none for HFpEF. All 11 drugs reduced mortality and morbidity except for digoxin, which only reduced hospitalization for heart failure. This state-of-the-art review examines the evidentiary support for regulatory actions and incorporation into guidelines of heart therapies approved since 2015.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kaul. Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines. J Am Coll Cardiol. 2025. PMID: 40835369. doi:10.1016/j.jacc.2025.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。